The nurse administers a drug to a patient whose heart rate is bradycardic aimed at increasing heart rate and myocardial activity. What adrenergic receptor is this drug stimulating?

A) Celecoxib (Celebrex):
Celecoxib is a selective COX-2 inhibitor that targets the cyclooxygenase-2 enzyme, which is primarily responsible for inflammation, pain, and fever. COX-2 inhibitors tend to cause less gastrointestinal irritation compared to nonselective NSAIDs like aspirin, which block both COX-1 and COX-2 enzymes. Because aspirin is causing gastrointestinal upset, switching to Celecoxib, which is less likely to irritate the stomach lining, may be an appropriate option to prevent myocardial infarction while minimizing gastrointestinal discomfort.

B) Enteric-coated aspirin:
Enteric-coated aspirin is designed to dissolve in the small intestine rather than the stomach, which may reduce some gastrointestinal irritation. However, it does not eliminate the risk entirely, and it still functions as a COX-1 inhibitor. If the patient is already experiencing gastrointestinal upset, simply switching to enteric-coated aspirin may not be sufficient to alleviate the discomfort, and other options should be considered.

C) Nabumetone (Relafen):
Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) with some COX-2 selectivity. While it may cause less gastrointestinal upset than non-selective NSAIDs like aspirin, it is still an NSAID and carries a risk of gastrointestinal side effects, especially with prolonged use.
D) A COX-2 inhibitor:
While COX-2 inhibitors, including Celecoxib, are typically effective in reducing inflammation and pain with fewer gastrointestinal side effects than traditional NSAIDs, the term "a COX-2 inhibitor" could refer to various drugs, and Celecoxib (Celebrex) is the most commonly used.

A) Tacrine (Cognex): Tacrine is an acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease to improve cognitive function. It is not typically used for Parkinson's disease, which is characterized by motor symptoms such as tremors, shuffling gait, and rigidity.

B) Rivastigmine (Exelon): Rivastigmine is another acetylcholinesterase inhibitor, similar to Tacrine, primarily used to treat Alzheimer's disease or dementia-related symptoms. While it helps with cognitive symptoms, it is not effective in treating the motor symptoms of Parkinson's disease.

C) Carbidopa-levodopa (Sinemet): This is the correct answer. Carbidopa-levodopa (Sinemet) is the gold standard treatment for Parkinson's disease. Levodopa is a precursor to dopamine, which helps address the dopamine deficiency in the brain that causes symptoms like tremors, shuffling gait, and lack of facial expression (masked facies). Carbidopa is added to prevent levodopa from being broken down before it reaches the brain, enhancing its effectiveness.

D) Donepezil (Aricept): Donepezil is also an acetylcholinesterase inhibitor used primarily in Alzheimer's disease. Like Tacrine and Rivastigmine, it works to improve cognitive function but does not treat the motor symptoms seen in Parkinson's disease. It would not be appropriate for managing the patient's Parkinsonian symptoms.